期刊文献+

PDE4B基因过表达对弥漫大B细胞淋巴瘤患者的预后价值 被引量:7

Prognostic significant of overexpressed phosphodiesterase 4B in patients with diffuse large B-cell lymphoma
原文传递
导出
摘要 目的探讨磷酸二酯酶4B(phosphdiesterase 4B,PDE4B)基因过表达对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者预后的影响,并分析其预后价值。方法从GEO(gene expression omnibus)数据库获得320例DLBCL患者的基因芯片数据,比较PDE4B基因过表达与正常表达患者生存率的差异。构建单变量国际预后指数(international prognostic index,IPI)、PDE4B和多变量(IPI+PDE4B)Cox比例风险模型,并用时点/动态受试者工作曲线(receiver operating characteristic curves,ROC)法分析模型的预测能力随时间的变化趋势,一致性统计量C用于评价和比较各模型的预测准确度。结果 PDE4B基因过表达的患者死亡的风险是正常表达的1.431倍(HR=1.431,95%CI:1.013~2.002,P=0.042)。多变量模型的C统计量与单变量模型相比,差异有统计学意义(IPI vs.IPI+PDE4B:Z=15.0,P<0.001;PDE4B vs.IPI+PDE4B:Z=53.7,P<0.001)。结论 PDE4B基因过表达是DLBCL患者预后的危险因素,结合IPI和PDE4B基因能提高DLBCL的预后准确性。 Objective This study used to investigate the association between overexpressed phosphdiesterase 4B (PDE4B) and the prognosis of diffuse large B-cell lymphoma (DLBCL) and evaluate its predictive values.Methods Micro-array data of 320 patients with DLBCL was downloaded from gene expression omnibus (GEO) data set.The statistically significant test of overall survival (OS) between high and normal PDE4B expression level was made by Log-rank test.Univariate (international prognostic index,IPI or PDE4B) and multivariate (IPI + PDE4B) Cox proportional hazards model were constructed and time-dependent receiver operating characteristic curves method was used to analysis the tendency of model's predictive power over time.The overall prediction accuracy of each model was evaluated and compared with the C index.Results The risk of death in DLBCL patients with overexpressed PDF4B was 1.431 times (HR =1.431,95% CI:1.013-2.002,P =0.042) that of normal expression.C index was statistically significant difference (IPI vs.IPI + PDE4B:Z =15.0,P 〈 0.001;PDF4B vs.IPI + PDF4B:Z =53.7,P 〈 0.001) between multivariate and univariate Cox regression model.Conclusions Overexpressed PDE4B is a hazard for DLBCL.Prognostic accuracy of DLBCL may be improved by combining IPI and PDE4B.
出处 《中华疾病控制杂志》 CAS CSCD 北大核心 2017年第5期510-513,共4页 Chinese Journal of Disease Control & Prevention
基金 国家自然科学基金(81473073)
关键词 环核苷酸磷酸二酯酶类 4型 淋巴瘤 B细胞 基因表达 预后 Cyclic nucleotide phosphodiesterases, type 4 Lymphoma, B-cell Gene expression Prognosis
  • 相关文献

参考文献6

二级参考文献87

  • 1顾霞,林汉良,沈艳,茹景顺,周伟,孙艺.不同类型淋巴瘤中survivin和bcl-2的表达及意义[J].临床与实验病理学杂志,2005,21(2):159-163. 被引量:11
  • 2汤慧芳,陈季强,王鹏.磷酸二酯酶4作为抗炎药物靶点的研究现状及未来发展方向[J].中国药科大学学报,2006,37(1):9-13. 被引量:9
  • 3阳文捷,宋向群.Bcl-2和Bcl-6与淋巴瘤相关性的研究进展[J].中华肿瘤防治杂志,2006,13(22):1755-1758. 被引量:8
  • 4Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 5Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 6Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 7Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 8Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 9Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 10Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.

共引文献281

同被引文献20

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部